**Supplemental table 4:** Relationship between *GPR126* transcript level and standard clinical pathological and biological parameters in bladder cancer

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total population (%)** | ***GPR126* mRNA overexpression** | ***GPR126* mRNA no overexpression** | ***p* \*** |
| **n (%)** | **n (%)** |
|  |  |  |  |  |
| **Total population** | 103 (100.0) | 47 (45.6) | 56 (54.4) |  |
| **Age** (years) |  |  |  |  |
| ≥60 | 77 (74.8) | 35 (45.5) | 42 (54.5) | 0.95 |
| <60 | 26 (25.2) | 12 (46.2) | 14 (53.8) |  |
| **Sex** |  |  |  |  |
| Male | 86 (83.5) | 41 (47.7) | 45 (52.3) | 0.35 |
| Female | 17 (16.5) | 6 (35.3) | 11 (64.7) |  |
| **Smoking status** a |  |  |  |  |
| Non-smoker | 28 (28.9) | 13 (46.4) | 15 (53.6) | 0.90 |
| Smoker | 69 (71.1) | 33 (47.8) | 36 (52.2) |  |
| **History of NMIBC** |  |  |  |  |
| No | 59 (57.3) | 26 (44.1) | 33 (47.8) | 0.71 |
| Yes | 44 (42.7) | 21 (47.7) | 23 (52.3) |  |
| **Associated pTis** |  |  |  |  |
| No | 94 (91.3) | 44 (46.8) | 50 (53.2) | 0.67 |
| Yes | 9 (8.7) | 3 (33.3) | 6 (66.7) |  |
| ***FGFR3* status** |  |  |  |  |
| Mutated | 28 (27.2) | 14 (50.0) | 14 (50.0) | 0.59 |
| No mutation | 75 (72.8) | 33 (44.0) | 42 (56.0) |  |
| ***PIK3CA* status** |  |  |  |  |
| Mutated | 13 (12.6) | 6 (46.2) | 7 (53.8) | 0.97 |
| No mutation | 90 (87.4) | 41 (45.6) | 49 (54.4) |  |

\* Chi2 test, Chi2 test with Yates’ correction if appropriate

a data available for 97 patients